KR20160145617A - 1,1''-(1,6-디옥소-1,6-헥산디일)비스-ｄ-프롤린의 프로드럭 - Google Patents
1,1''-(1,6-디옥소-1,6-헥산디일)비스-ｄ-프롤린의 프로드럭 Download PDFInfo
- Publication number
- KR20160145617A KR20160145617A KR1020167029703A KR20167029703A KR20160145617A KR 20160145617 A KR20160145617 A KR 20160145617A KR 1020167029703 A KR1020167029703 A KR 1020167029703A KR 20167029703 A KR20167029703 A KR 20167029703A KR 20160145617 A KR20160145617 A KR 20160145617A
- Authority
- KR
- South Korea
- Prior art keywords
- sap
- compound
- formula
- disease
- amyloidosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- KSKLDMGKWDUQCT-DNQXCXABSA-N O=C(CCCCC(N(CCC1)[C@H]1C(OCOC(OC1CCOCC1)=O)=O)=O)N(CCC1)[C@H]1C(OCOC(OC1CCOCC1)=O)=O Chemical compound O=C(CCCCC(N(CCC1)[C@H]1C(OCOC(OC1CCOCC1)=O)=O)=O)N(CCC1)[C@H]1C(OCOC(OC1CCOCC1)=O)=O KSKLDMGKWDUQCT-DNQXCXABSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1407506.3 | 2014-04-29 | ||
| GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
| PCT/EP2015/058998 WO2015165833A1 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160145617A true KR20160145617A (ko) | 2016-12-20 |
Family
ID=50972033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167029703A Ceased KR20160145617A (ko) | 2014-04-29 | 2015-04-27 | 1,1''-(1,6-디옥소-1,6-헥산디일)비스-ｄ-프롤린의 프로드럭 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9701668B2 (https=) |
| EP (1) | EP3137457B1 (https=) |
| JP (1) | JP6445046B2 (https=) |
| KR (1) | KR20160145617A (https=) |
| CN (1) | CN106459016B (https=) |
| AR (1) | AR100204A1 (https=) |
| AU (1) | AU2015252184B2 (https=) |
| BR (1) | BR112016025129A2 (https=) |
| CA (1) | CA2947060C (https=) |
| CL (1) | CL2016002721A1 (https=) |
| CR (1) | CR20160508A (https=) |
| DO (1) | DOP2016000292A (https=) |
| EA (1) | EA032129B1 (https=) |
| ES (1) | ES2731253T3 (https=) |
| GB (1) | GB201407506D0 (https=) |
| IL (2) | IL248249A0 (https=) |
| MA (1) | MA39406B1 (https=) |
| MX (1) | MX2016014246A (https=) |
| MY (1) | MY191088A (https=) |
| PE (1) | PE20161558A1 (https=) |
| PH (1) | PH12016502006A1 (https=) |
| SG (1) | SG11201608371RA (https=) |
| TW (1) | TWI676624B (https=) |
| UA (1) | UA119871C2 (https=) |
| UY (1) | UY36098A (https=) |
| WO (1) | WO2015165833A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0915088B1 (en) | 1997-10-31 | 2002-09-18 | F. Hoffmann-La Roche Ag | D-Proline derivatives |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| CA2528065A1 (en) | 2003-06-05 | 2004-12-16 | Pfizer Products Inc. | Beta-lactamase inhibitor prodrug |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| CA2604206A1 (en) | 2005-04-12 | 2006-10-19 | Meiji Seika Kaisha, Ltd. | 2-thioethenyl substituted carbapenem derivatives |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/en not_active Ceased
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja not_active Expired - Fee Related
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Ceased
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
- 2015-04-27 CA CA2947060A patent/CA2947060C/en active Active
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/en active Active
- 2015-04-27 US US14/787,608 patent/US9701668B2/en not_active Expired - Fee Related
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en not_active Ceased
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006A1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en not_active Expired - Fee Related
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112105360B (zh) | 用于癌症治疗的bcl-2蛋白降解剂 | |
| CN101977915A (zh) | 大环丝氨酸蛋白酶抑制剂 | |
| CA2676920A1 (en) | Piperidine derivatives | |
| US9737505B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
| KR20160145617A (ko) | 1,1''-(1,6-디옥소-1,6-헥산디일)비스-ｄ-프롤린의 프로드럭 | |
| US20240208940A1 (en) | Small-molecule inhibitors for beta-catenin/bcell lymphoma 9 protein-protein interaction | |
| EP4519272A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| JP7053762B2 (ja) | Ｓａｐ枯渇剤としてのｄ－プロリン誘導体 | |
| US20050119163A1 (en) | SH2 domain binding inhibitors | |
| JP2021520412A (ja) | タンパク質ミスフォールディング疾患のための療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161025 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200427 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220113 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221122 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230526 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20221122 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20220113 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |